This year was a year of firsts for catheter-based innovations, most notably for renal denervation and pulsed field ablation. ReCor Medical won an FDA panel nod for its renal denervation system in August. The panel voted in favor of the safety and efficacy of its Paradise ultrasound renal denervation (RDN) system for treating hypertension. The … [Read more...] about The 10 most-read catheter-based innovation stories of 2023
urotronic
Laborie acquires drug-coated balloon maker Urotronic
Laborie Medical Technologies announced today that it completed the acquisition of drug-coated balloon developer Urotronic. The companies struck an agreement last month for Laborie to buy Urotronic for up to $600 million. Urotronic developed the Optilume DCB used in interventional urology procedures. It treats urethral strictures and benign … [Read more...] about Laborie acquires drug-coated balloon maker Urotronic
FDA approves drug-coated balloon for BPH symptoms from Urotronic
Urotronic announced that the FDA approved its Optilume BPH catheter system for alleviating urinary symptoms caused by BPH. Minneapolis-based Urotronic designed Optilume as a minimally invasive surgical therapy. It combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel. This treats … [Read more...] about FDA approves drug-coated balloon for BPH symptoms from Urotronic
Laborie acquires exclusive license for drug-coated baloon treatment for urethral strictures
Laborie Medical Technologies announced today that it acquired an exclusive license to the Optilume urethral drug-coated balloon (DCB). Portsmouth, New Hampshire-based Laborie purchased a perpetual, exclusive license to Optilume — developed by Urotronic — following FDA approval in December 2021. The DCB platform received CE mark approval for use … [Read more...] about Laborie acquires exclusive license for drug-coated baloon treatment for urethral strictures
FDA approves Urotronic’s Optilume drug coated balloon for urethral strictures
Urotronic today announced that it received FDA approval for its Optilume urethral drug-coated balloon for male urethral strictures. Plymouth, Minnesota–based Urotronic designed the paclitaxel-coated balloon to inhibit new scar tissue growth that can occur after endoscopic dilations. Urethral strictures are scars in or around the urethra that can … [Read more...] about FDA approves Urotronic’s Optilume drug coated balloon for urethral strictures
